Parkinson’s disease in Sweden—resource use and costs by severity

To estimate resource use and costs, including direct and indirect costs, in relation to levels of severity in individuals with Parkinson's disease (PD) in a Swedish setting.

[1]  Yoshihiro Kokubo,et al.  Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The Lancet Neurology.

[2]  G. Tamás,et al.  Quality of Life and Costs in Parkinson's Disease: A Cross Sectional Study in Hungary , 2014, PloS one.

[3]  G. Ljunggren,et al.  Drug and treatment costs in Parkinson’s disease patients in Sweden , 2012, Acta neurologica Scandinavica.

[4]  K. Bötzel,et al.  Costs of illness and care in Parkinson's Disease: An evaluation in six countries , 2011, European Neuropsychopharmacology.

[5]  L. Findley,et al.  The economic burden of advanced Parkinson’s disease: an analysis of a UK patient dataset , 2010, Journal of medical economics.

[6]  W. Oertel,et al.  Costs of Parkinson’s Disease and Antiparkinsonian Pharmacotherapy: An Italian Cohort Study , 2010, Neurodegenerative Diseases.

[7]  Ulf Persson,et al.  Resource use and costs in a Swedish cohort of patients with Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[8]  A Schrag,et al.  How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population , 2000, Movement disorders : official journal of the Movement Disorder Society.

[9]  S. Wilson.  Methods for the economic evaluation of health care programmes , 1987 .

[10]  M. Hoehn,et al.  Parkinsonism , 2020, Definitions.

[11]  W. Oertel,et al.  Cost of illness and its predictors for Parkinson’s disease in Germany , 2012, PharmacoEconomics.